In response to the COVID-19 pandemic, Dr. Kaszynski co-founded the "Global Unified plAtform for the Rapid Development and Investigation of therapeutics for Novel Pandemics (GUARDIAN)" program in collaboration with the Imperial College (London) to optimize clinical studies during outbreaks and pandemics. Dr. Kaszynski is one of the few physician-scientists with operational and academic experience involving the use of favipiravir and has been instrumental in establishing international COVID-19 clinical trials spanning five continents. As a Senior Medical Advisor to the Democratic Republic of Congo (DRC), Dr. Kaszynski worked together with the Coordinator General of the Ebola response to identify and implement novel strategies to help combat/contain the Ebola outbreak. It was during the 2019 Ebola outbreak in the North Kivu and Ituri provinces in the DRC where Dr. Kaszynski, together with the DRC Ministry of Foreign Affairs and the Coordinator General for the Ebola outbreak agreed upon proposals for operational deployment of favipiravir in a post-exposure prophylactic capacity. Dr. Kaszynski holds a Doctor of Medicine from Kobe University (Japan) and was a Fellow at Harvard Medical School, Massachusetts General Hospital in the Department of Anesthesia, Critical Care and Pain Medicine (Boston, MA).